In September 2009, Novartis Vaccines & Diagnostics and Ezequiel Dias Foundation (FUNED) signed a strategic alliance. The goal of this alliance is to supply Menjugate® meningococcal C conjugate vaccine for Brazil’s National Immunization Program (PNI).This project began with Novartis supplying Menjugate to the state of Minas Gerais. In July 2010, it was included in the National Immunization Program. It has been structured to ensure in the short and long term the vaccination against Meningitis C of all Brazilian children up to two years of age. Novartis Vaccines & Diagnostics will produce the vaccine during the initial phases of the project while a complete technology transfer to FUNED is conducted. This will allow for production of the vaccine while technology transfer is ongoing.
This partnership enables supply of an agreed number of vaccine doses per year, which can help protect children from this devastating disease. This partnership will ultimately make Brazil self-sufficient in meningococcal C conjugated vaccine. The project duration is 5 years, with the option to extend it, if justified. At the end of the contract, NVD will have transferred to FUNED all production steps ensuring self-sufficiency. To address the challanges of complexity of the technology and multicultural nature of the partnership, a global project management structure has been implemented for optimum interaction among the countries involved and to ensure fast decision and continuous learning processes derived from the technology transfer.
|Location||Brazil, Latin America and Caribbean|